MediaTek unveils Helio G36 chip to power gaming smartphones in India - New Delhi News
by Maria Thomas
Updated Feb 13, 2023
With high-quality Portrait bokeh and light AI camera enhancements, the new processor is designed to level up the entry gaming smartphones with the benefits of a bigger camera, sustained performance, faster displays, and global dual 4G connectivity with intelligent connectivity technologies, said the company.
The key features of MediaTek Helio G36 include -- support for up to 50MP cameras, with dual camera photography backed by a hardware depth engine for high-quality Depth of Field (Bokeh) effects, fast HD+ 90Hz displays that give users notably smoother scrolling of webpages, shopping, social, integrated Wi-Fi 5 and Bluetooth 5 support simultaneous co-existence to significantly boost throughput and connection reliability when using peripherals like headphones and gamepads, among others.
Moreover, the chipset comes equipped with MediaTek HyperEngine 2.0 Lite with Resource Management Engine 2.0 that ensures intelligent performance optimization and dynamic management of CPU, and GPU for sustained performance and longer gameplay even in games with demanding action.
The chipmaker further mentioned that the new chipset is built using the all in a highly power-efficient TSMC (Taiwan Semiconductor Manufacturing Company) 12nm chip production process.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report